Open Access

Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma

  • Authors:
    • Jun Kurai
    • Hiroki Chikumi
    • Kiyoshi Hashimoto
    • Miyako Takata
    • Takanori Sako
    • Kosuke Yamaguchi
    • Naoki Kinoshita
    • Masanari Watanabe
    • Hirokazu Touge
    • Haruhiko Makino
    • Tadashi Igishi
    • Hironobu Hamada
    • Seiji Yano
    • Eiji Shimizu
  • View Affiliations

  • Published online on: August 24, 2012
  • Pages: 1610-1618
  • Copyright: © Kurai et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Epidermal growth factor receptor (EGFR) is commonly overexpressed in malignant pleural mesothelioma (MPM). Cetuximab is a chimeric mouse-human antibody targeted against EGFR and induces potent antibody-dependent cellular cytotoxicity (ADCC). The action of cetuximab against MPM cells has not been well studied. Therefore, in this study, we investigated the antitumor activity of cetuximab against MPM cell lines, particularly with respect to ADCC activity in vitro and in vivo. EGFR expression of MPM cells was measured by a quantitative flow cytometric analysis and immunohistochemistry. The effect of cetuximab on growth inhibition was assessed using a modified MTT assay. The ADCC activity was measured by a 4-h 51Cr release assay using fresh or IL-2-activated peripheral blood mononuclear cells. In vivo antitumor activity of cetuximab was evaluated using an orthotopic implantation mouse model. Cetuximab-mediated ADCC activity against MPM cells was observed at low concentration (0.25 mg/ml) and was enhanced by IL-2, whereas no direct effect on growth inhibition was detected. A logarithmic correlation was observed between the number of EGFRs on MPM cells and ADCC activity. Low EGFR expression on the MPM cells, which was weakly detectable by immunohistochemistry, was sufficient for maximum ADCC activity. In the mouse model, cetuximab treatment with or without IL-2 significantly inhibited intrathoracic tumor growth and prolonged their survival. Our study shows that cetuximab has potent anti-MPM activity both in vitro and in vivo, mainly through the immunologic mechanism of ADCC. Cetuximab has the potential to be used as a novel therapy for MPM patients.


Malignant pleural mesothelioma (MPM) is a rare and highly aggressive neoplasm, which arises from the pleural, pericardial, or peritoneal lining. Most patients with MPM have a history of exposure to carcinogenic asbestos fibers (1,2), particularly those of the amphibole type, or to naturally occurring erionite in some regions of Turkey (3,4). Although surgery, chemotherapy, radiotherapy, and combinations thereof play an important role in the treatment of MPM patients, the median survival of patients treated for MPM is dismal, at only 6–18 months (57). Despite advances in modern systemic chemotherapy using the combination of pemetrexed and cisplatin, long-term survival in patients with MPM remains limited (8). Therefore, more specific, effective, and less toxic therapies are needed. Research into the molecular pathways of MPM has led to novel targeted strategies that inhibit specific key molecules in tumor growth and progression.

Epidermal growth factor receptor (EGFR) is a tyrosinekinase (TK) receptor involved in cell death and proliferation, cell motility, angiogenesis, and extracellular matrix composition (9). EGFR is overexpressed in many human malignancies, including lung, head and neck, colorectal, and breast cancers, where it is variably associated with patient prognosis (10,11). EGFR is reported to be overexpressed in 44–97% of MPM patients, as determined by various immunohistochemical studies with variability in outcomes (1215). In a recent study, Destro et al demonstrated that both the immunohistochemical expression and corresponding mRNA levels of EGFR were higher in tumor specimens than in normal pleural samples (12). These data confirmed those of a previous study suggesting that EGFR could play an important role in the oncogenic phenotype of MPM disease (9).

Two types of EGFR inhibitors have been developed: small molecule EGFR tyrosine kinase inhibitors (TKIs) (16,17) and monoclonal antibodies directed against the extracellular domain of EGFR (1820). Gefitinib, a quinazoline derivative, is the first TKI developed that specifically inhibits the activation of EGFR TK through competitive binding to the ATP-binding domain of the receptor. Gefitinib has been shown to be effective in preclinical studies and clinical trials, and it received approval for use in Japan in patients with advanced non-small cell lung cancer refractory to chemotherapy in July 2002. Subsequently, it has gained approval in over 30 countries, including the United States. Gefitinib reduced the proliferation of MPM cells by inhibiting the EGFR signaling pathway in vitro(9); however, the clinical study revealed that gefitinib was not active in MPM patients (21). The same is true of erlotinib (14). These disappointing results for EGFR TK inhibitors have led to increased interest in monoclonal antibodies directed against EGFR, because these 2 classes of agents may have substantially different mechanisms of action.

Cetuximab is a chimeric mouse-human antibody directed against the extracellular domain of EGFR (22), thereby inhibiting the binding of activating ligands to the receptor. Consequently, cetuximab inhibits ligand-dependent activation of the EGFR and inhibits the downstream pathways that cause cell cycle progression, cell growth, and angiogenesis. In addition, the binding of cetuximab initiates EGFR internalization and degradation that leads to signal termination (2325). In addition to these direct inhibitory effects to EGFR signaling, cetuximab potentially provokes immunologic antitumor effects called antibody-dependent cellular cytotoxicity (ADCC). This effect takes place in the presence of the host effector system, such as natural killer (NK) cells, because cetuximab has a human IgG1 backbone. Recently, we and others showed that this ADCC activity is crucial for the antitumor effects of cetuximab (2628). Because this immunological mechanism is not activated by TKIs, cetuximab is expected to have more potent antitumor activities against MPM than TKIs, especially in vivo. However, no published in vitro or in vivo studies have focused on the effect of cetuximab against MPM cells, particularly with respect to ADCC activity.

In the present study, we investigated the biologic activity of cetuximab against a panel of MPM cells with respect to ADCC activity and the survival effects of intrathoracic treatment using an orthotopic implantation mouse model that reproduces the clinical behavior and therapeutic responsiveness of MPM in humans.

Materials and methods

Cell lines and cell culture

Five MPM cell lines (EHMES-1, MSTO-211H, H2052, EHMES-10 and H28) and an epidermoid carcinoma cell line (A431) were used in this study. MSTO-211H, H2052, H28 and A431 were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). The other lines (EHMES-1, EHMES-10) were established from the pleural effusion of a patient with MPM at Ehime University (Ehime, Japan). All cell lines were maintained in RPMI-1640 supplemented with 10% FCS, 50 U/ml penicillin, 50 U/ml streptomycin and 2.05 mmol/l glutamine. The cells were incubated at 37°C in 5% CO2.

Monoclonal antibody

Cetuximab was obtained from Bristol-Myers Squibb (New York, NY, USA). Rituximab, used as a control antibody, was obtained from Chugai Pharmaceutical (Tokyo, Japan). Anti-EGF receptor antibody (clone 528) for flow cytometry was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-EGF receptor antibody (clone 31G7) for immunohistochemical analysis was obtained from Zymed (South San Francisco, CA, USA).

Flow cytometric analysis

Cell surface EGFR expression of MPM cell lines was examined by flow cytometry (Becton-Dickinson, Franklin Lakes, NJ, USA) using a monoclonal antibody (clone 528). To determine the absolute number of antibody-binding sites per cell, we carried out a quantitative flow cytometric analysis using Dako QIFIKIT (DakoCytomation, Copenhagen, Denmark). Briefly, 1×104 cells were incubated for 1 h at 4°C with 0.4 μg of the primary antibody or the isotype-control IgG2a antibody (Sigma-Aldrich, St. Louis, MO, USA) in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA) and 0.01% sodium azide. After washing thrice with PBS, cells were incubated for 1 h with FITC-conjugated anti-mouse IgG (DakoCytomation) at 4°C. Similar to samples labeled with FITC-conjugated anti-mouse IgG from this kit, standard beads coated with a known amount of mouse IgG molecules were labeled with this secondary antibody. The labeled samples were washed thrice with PBS and analyzed using FACScan flow cytometer (Becton Dickinson). The number of antibody binding sites per cell was calculated by comparing the mean fluorescent intensity (MFI) value of the labeled cells with a calibration curve obtained by regression analysis of the MFI values of the standard beads.

Growth inhibition assay

Cell viability was assessed using the 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)2H-tetrazolium monosodium salt (WST-8) assay (Dojindo, Kumamoto, Japan). Cells were plated at 3×104 cells/well in triplicate in 96-well plates in complete medium. Following an overnight incubation, cetuximab (0-1,000 μg/ml) was added in varying concentrations and incubated. After 72 h, WST-8 solution (Dojindo) was added to each well, followed by incubation for 4 h at 37°C, and absorbance was measured using a Model 680 microplate reader (Bio-Rad Laboratories, Hercules, CA, USA) at test and reference wavelengths of 450 and 655 nm, respectively. Cell viability was calculated by dividing the mean absorbance of wells containing treated cells by those of control wells with untreated cells. The concentration of cetuximab resulting in 50% growth inhibition (IC50) was calculated. All experiments were done at least in triplicate and repeated at least 3 times.

Isolation of peripheral blood mononuclear cells (PBMCs) and interleukin-2 (IL-2) treatment

PBMCs were isolated from heparinized peripheral blood by lymphocyte-separation-medium (MP Biomedicals, Irvine, CA, USA) density gradient centrifugation. To investigate the effect of IL-2 (Sigma-Aldrich) on ADCC activity, PBMCs (106 cells/ml) were pre-incubated at 37°C for up to 18 h before cytotoxic assay in the presence of IL-2 (30 IU/ml) (2931). Blood samples were collected at Tottori University in accordance with the Tottori University Review Board, and the healthy individuals provided written informed consent.

Test for ADCC and NK activity

After the target MPM cells were labeled with 100 μCi 51Cr (PerkinElmer Life and Analytical Sciences, Boston, MA, USA) for 60 min, target cells (104/well) and effector cells at various effector:target (E/T) ratios were co-incubated in 200 μl of DMEM or RPMI-1640 in a 96-well U-bottomed plate in triplicate for 4 h at 37°C with 0.5 μg/ml of cetuximab (Bristol-Myers Squibb) or control antibody, rituximab (Chugai Pharmaceutical). Next, the amount of radioactivity in the supernatant liquid was measured by a gamma counter. The percentage of specific cytolysis was calculated as previously described (27). ADCC activity was calculated as the percentage of lysis in the presence of cetuximab minus the percentage of lysis in the presence of control antibody that is attributed to NK activity.

Immunohistochemical analysis

Paraffin-embedded cell blocks were prepared from each MPM cell lines, which were fixed in 4% paraformaldehyde. Tissue sections (3 μm) were de-waxed in xylene, rehydrated through a graded series of ethanol solutions, rinsed in distilled water for 5 min, and then immersed in 0.6% hydrogen peroxide in methanol for 30 min to block endogenous peroxidase. For antigen retrieval, the sections then were microwaved in 0.01 mol/l of sodium citrate-buffered saline, pH 6.0, for 20 min at 92°C using a Microwave Processor model MI-77 (Azumaya, Tokyo, Japan). After rinsing in PBS for 5 min, the slides were pre-blocked with 10% normal rabbit serum at room temperature for 20 min and incubated at 4°C overnight with the primary antibody, anti-EGF receptor antibody (clone 31G7) (Zymed). The immunoreaction was visualized with 3.3′-diaminobenzidine and 100 μl of hydrogen peroxidase in 0.05 M Tris-HCl buffer, pH 7.6. Finally, the slides were counterstained with a 0.1% hematoxylin solution. The staining results were measured semiquantitatively on a scale of 0, 1+, 2+ and 3+ as follows: 0, no membranous staining in any of the cells; 1+, weak intensity membranous and cytoplasmic staining of nearly equal intensity; 2+, moderate to strong intensity staining predominantly in the membranes; and 3+, strong intensity staining clearly localized to the cell membranes. Representative examples of 0, 1+, 2+ and 3+ IHC staining for EGFR are demonstrated in Fig. 1. We performed the staining for the each cell line 3 times, and the intensity was evaluated by 2 independent pathologists.


Male C.B-17 SCID mice (5 weeks) were obtained from CLEA Japan (Osaka, Japan) and maintained under specific pathogen-free conditions throughout the study. Experiments were carried out in accordance with the guidelines established by the Tottori University Committee on Animal Care and Use.

Orthotopic implantation model

The cultured MSTO-211H cells were harvested by pipetting. The cells were washed 3 times and resuspended in Ca2+- and Mg2+-free PBS. For orthotopic implantation, SCID mice were anesthetized with ether and had their right chest wall shaved. After sterilization of the chest wall with 70% ethanol, the right chest skin and subcutaneous tissue was cut, and the parietal pleura was exposed. Thereafter, the tumor cells (106/100 μl PBS) were injected into the thoracic cavity of SCID mice using a 27G needle as described previously (32). Finally, the incisions were sutured to close the wound. The mice were treated with cetuximab (0.05 mg/mouse i.t.) or in combination with IL-2 (30 IU/ml i.t.) using the same methods on day 7, and sacrificed on day 21 to evaluate tumor development. The pleura-disseminated tumors were inspected macroscopically.

Area measurements

The intrathoracic tumor area was manually defined on intrathoracic pictures, and was measured with the image analysis software program Scion Image for Windows (PC version of NIH Image).


The statistical comparison between the 2 groups was analyzed using Student’s t-test. The survival times of SCID mice bearing MSTO-211H cells was determined using the Kaplan-Meier estimation (PRISM for Windows; GraphPad Software, La Jolla, CA, USA).


Analysis of EGFR expression in MPM cell lines using flow cytometry and IHC

We first examined the expression of EGFR in 5 MPM cell lines. A431, an epidermoid carcinoma cell line, was used as a positive control for EGFR expression in most studies, since it has been reported to express high levels of EGFR (33,34). We measured the number of EGFRs on each MPM cell line by quantitative flow cytometric analysis (Dako QIFIKIT) (35) and compared them to the evaluation by immunohistochemistry (IHC) (scored from 0 to 3+). As shown in Table I, the level of EGFR expression in each MPM cell line, in ascending order, is as follows: EHMES-1, MSTO-211H, H2052, EHMES-10 and H28. As assessed using IHC, 2 cell lines (EHMES-1 and MSTO-211H), which express a low number of EGFRs (ranging from 6.54×103 to 1.42×104/cell), were stained and scored as 1+. The other 3 cell lines of MPM, which expressed moderate numbers of EGFR (ranging from 2.73×104 to 4.51×104/cell), were scored as 2+. The positive control cell line A431, expressing a large number of EGFRs (3.51×106/cell) scored 3+ (data not shown) (Fig. 1). These results indicated a good correlation between the number of EGFR molecules on the cells and their EGFR status as estimated by IHC.

Table I.

EGFR expression analysis by quantitative flow cytometry and IHC in malignant pleural mesothelioma cell lines.

Table I.

EGFR expression analysis by quantitative flow cytometry and IHC in malignant pleural mesothelioma cell lines.

Cell linesEGFR expression (nos. of EGFR/cells)Immunohistochemical score
EHMES-1 6.54×1031+
MSTO-211H 1.42×1041+
H2052 2.73×1042+
EHMES-10 3.16×1042+
H28 4.51×1042+
Direct effects of cetuximab on growth inhibition in MPM cells

We next examined the effect of cetuximab against the proliferation of MPM cells using the WST-8 assay, which is a modified MTT assay. We found that all MPM cell lines were completely resistant to cetuximab treatment irrespective of the surface amount of EGFR (Fig. 2). These data suggest that direct growth inhibitory effects would not be expected in the anti-MPM action of cetuximab.

Cetuximab-mediated cytotoxicity against MSTO-211H cells by healthy human PBMCs

To test whether cetuximab induces ADCC activity against MPM cell lines, we performed a 4-h 51Cr release assay of MSTO-211H cells that weakly express EGFR using human PBMCs at various E/T ratios (Fig. 3A). While low levels of cytolysis of MSTO-211H cells were induced by PBMCs at the higher E/T ratios of 80:1 and 40:1 in the absence of cetuximab (known as NK activity), the lytic activity of PBMCs increased significantly in the presence of cetuximab at both E/T ratios. There was no significant increase in lytic activity in the presence of the control antibody, rituximab (data not shown). These data suggest that cetuximab was capable of inducing ADCC activity efficiently, even against MPM cells that weakly express EGFR.

Next, to identify the optimal cetuximab concentration for ADCC activity, we determined the ADCC activity with increasing concentrations of cetuximab, ranging from 2.5×10−6 to 1,000 mg/ml at an E/T ratio of 20:1. As shown in Fig. 3B, cetuximab-mediated ADCC activity against MSTO-211H cells was already detectable at a concentration of 2.5×10−3 mg/ml and was saturated at 0.25 mg/ml. These data indicate that a cetuximab concentration in excess of 0.25 mg/ml was sufficient for maximum ADCC activity. We used this concentration of cetuximab for the subsequent assays.

Cetuximab-mediated ADCC activity against MPM cell lines with various EGFR expression levels

To evaluate the correlation between the ADCC activity induced by cetuximab and EGFR expression levels on target MPM cells, we determined the ADCC activity in MPM cell lines with various EGFR expression levels at an E/T ratio of 40:1 in the presence of the optimal dose of cetuximab (0.25 mg/ml). As shown in Fig. 3C, the ADCC activity correlated logarithmically with the number of EGFR molecules expressed on the MPM cell surface. Near-maximum ADCC activity was observed in MSTO-211H cells, which have small numbers of EGFRs and scored 1+ by IHC. ADCC activity did not increase in cells with higher EGFR expression.

In addition, as IL-2 is known to activate PBMCs, we tested the effects of overnight treatment of PBMCs with IL-2 on cetuximab-mediated ADCC activity. Low doses of IL-2 increased ADCC activity in all cell lines, regardless of EGFR expression level (Fig. 3C). These data suggest that the very weak EGFR expression in MPM cells is enough to mediate ADCC activity and that IL-2 is capable of enhancing this activity.

Effect of cetuximab and IL-2 on SCID mice bearing MSTO-211H cells

To test the antitumor effects of cetuximab in vivo, we used an orthotopic implantation mouse model as a clinically relevant animal model. In this model, cells from the mesothelioma cell line MSTO-211H were implanted into the thoracic cavity of SCID mice, which possess robust NK cell activity (36). The implanted mice were treated with cetuximab by direct administration into the thoracic cavity with and without IL-2 on day 7, and then sacrificed on day 21 as described in Materials and methods. To determine the optimal dose of cetuximab for the treatment of SCID mice bearing MSTO-211H, we first determined the survival times of the mice using various amounts of cetuximab (0.5 mg/mouse, 0.05 mg/mouse and 0.005 mg/mouse i.t. on day 7). This preliminary experiment showed that there was no statistically significant difference in survival time between the mice (data not shown). In addition, in a separate study that evaluated the pharmacokinetics of cetuximab in nude mice bearing human colon carcinoma xenografts, the efficacious range for antitumor activity was demonstrated to be 0.04-1 mg/mouse (37). We therefore administered cetuximab at a dose of 0.05 mg/mouse in our subsequent in vivo experiments to ensure biological activity yet minimize side effects. As shown in Fig. 4A, cetuximab inhibited intrathoracic mesothelioma growth in the mice, and this inhibition was markedly enhanced by IL-2 co-administration. This inhibitory effect of cetuximab alone and its enhancement by the addition of IL-2 was confirmed by quantitative measurements of the tumor area using Scion Image Software (Fig. 4B). Furthermore, intrathoracic administration of cetuximab significantly prolonged the survival of the mice, and the combination of cetuximab with IL-2 tended to improve survival (Fig. 4C). These results suggest that cetuximab exerts antitumor effects against MPM cells in the presence of the mouse effector system, and that ADCC activity is highly involved in this effect.


In the present study, we evaluated cetuximab as a novel molecular targeting agent for MPM. We found that cetuximab induces potent ADCC activity but not growth inhibition against MPM cell lines. Cetuximab-induced ADCC activity has several characteristics that are relevant to clinical therapeutic applications. First, low concentrations of cetuximab are sufficient to induce maximum ADCC activity. Second, the low EGFR expression levels on MPM cells, which are scored as 1+ by IHC, could be sufficient for maximum ADCC activity mediated by cetuximab. Third, ex vivo IL-2 treatment of PBMCs can enhance cetuximab-mediated ADCC activity against MPM cell lines. Finally, intrathoracic administration of cetuximab in an orthotopic implantation mouse model significantly inhibited tumor growth and prolonged the survival time in the presence of the mouse effector system. These data indicate the important role of ADCC activity in the mechanism of action of cetuximab against cancer cells and underscore the promising potential of cetuximab as a new class of therapeutic agent for use against MPM.

In this study, we examined the correlation between the number of EGFRs on the cell surface and cetuximab-induced ADCC activity in MPM cells and found that there is a logarithmic relationship between them. This finding is in agreement with our previous observations and those reported by others in relation to other cancers. The ADCC activities of trastuzumab (38), anti-Ep-CAM antibody (39) and cetuximab (27) have been reported to weakly correlate with the logarithm of the number of target cell surface antigens in breast or lung cancer cells. The correlation observed in this study indicates that low EGFR expression levels could be sufficient for maximum ADCC activity of cetuximab against MPM cells and that an increase in the expression level of EGFR has no obvious effect on ADCC activity.

Our results indicate the possible usefulness of EGFR IHC as a predictive marker of the effectiveness of cetuximab-mediated ADCC activity against MPM cells. We demonstrated that the demarcation point of the EGFR expression level to achieve maximum ADCC activity is between EHMES-1 (6.54×103 EGFR molecules/cell) and MSTO-211H (1.42×104 EGFR molecules/cell), both of which are scored as 1+ by IHC. Therefore, near-maximum ADCC activity could be expected as long as the cells are stained by IHC, independent of the strength of the staining. This feature could circumvent a common weak point of IHC, as the semi-quantitative (40) nature of IHC makes it prone to inter-observer scoring error. In addition, IHC is superior to other methods for measuring EGFR levels in clinical specimens, such as a ligand binding assay (41) and quantitative flow cytometry (42), because it does not require isolation of cells from fresh tissue or special equipment. Therefore, IHC might be useful if it is scored simply as negative or positive when assessing a tumor sample for predicting the effectiveness of the ADCC activity of cetuximab.

We have demonstrated that cetuximab-mediated ADCC activity against MPM cell lines is enhanced in response to IL-2. This lymphokine is normally produced by T-lymphocytes and augments the function of effector cells, such as B cells, NK cells, T cells and monocytes (43). The combination of IL-2 and a therapeutic monoclonal antibody has been explored extensively in the case of rituximab (44,45) and trastuzumab (4649) and has been reported to enhance ADCC activity in vitro(50) or in vivo using mouse xenograft models (51). Based on these fundamental studies, several preclinical trials of these combination therapies have been conducted, including rituximab for B cell non-Hodgkin’s lymphoma (52) and trastuzumab for HER2-overexpressing cancer (53,54). Therefore, our observation that IL-2 enhances cetuximab-meditated ADCC activity against MPM cell lines might lend support to the future concurrent use of cetuximab and IL-2 in patients with MPM.

In our study, we showed that intrathoracic administration of cetuximab significantly inhibited tumor growth and prolonged the survival of mice. Several lines of evidences suggest that the anti-MPM effects of cetuximab in vivo are dependent on ADCC activity. First, murine spleen cells derived from SCID mice have been reported to induce ADCC activity against melanoma cells treated with cetuximab, though the effect is not as potent as that by parental mouse monoclonal antibodies against EGFR (26). In addition, several reports have described that the mouse effector system can induce the ADCC activity of human IgG1 antibody (55,56). Taken together, it can be concluded that mouse effector cells can bind to the Fc portion of human IgG to some extent, exerting some level of ADCC activity, if not its full activity. Second, our preliminary observation that there was no difference in survival times between mice treated with different amounts of cetuximab is strikingly similar to the dose-effector relationship of cetuximab-induced ADCC activity shown in vitro; that is, a cetuximab concentration in excess of 0.25 mg/ml is sufficient for maximum ADCC activity in vitro, and higher concentrations have no effect on the activity. Third, we used C.B-17 SCID mice, which lack mature T- and B-lymphocytes but possess robust NK cell activity (36). We have shown in a previous report that only NK cells are major effectors of cetuximab-mediated ADCC activity that is augmented by IL-2 (27). In parallel, IL-2 co-administration with cetuximab significantly inhibited MPM tumor growth in our model. Considering these data, we believe that our successful treatment of MPM in the SCID mouse model reflects cetuximab-induced ADCC activity and that future efforts to enhance this ADCC activity with effective adjuvants, such as cytokines (57), would be of vital importance.

This is the first study to investigate intrathoracic treatment by cetuximab for MPM. Because mesothelioma tends to remain localized in the pleural cavity for a long time, the development of local treatments would be promising. For this purpose, the orthotopic mouse model of MPM would be ideal for the evaluation of cetuximab, because MPM cells mimic the clinical behavior and progression of human MPM in this model (32). Local treatment with antitumor drugs offers a theoretical advantage, because the tumor is exposed directly to higher drug concentrations, while a lower incidence of toxic side effect can be expected. To date, several local treatments have been reported as successful in combination with other therapeutic modalities, such as surgery. These local treatments include intrathoracic chemotherapy (58), chemohyperthermia (59), and intraoperative photodynamic therapy (IPDT) (60). Our proposed combination therapy using cetuximab with IL-2 is preferable for the local treatment of MPM, because IL-2 causes serious side effects such as vascular leakage syndrome and systemic immuno-suppression if administered systemically (61). Local treatment may not be expected to cure MPM patients, but the improved local control of MPM in the thoracic cavity in combination with systemic treatment could offer potential benefits for MPM patients.

In this study, cetuximab treatment significantly inhibited intrathoracic MPM tumor growth, and the addition of IL-2 enhanced this activity. However, contrary to our expectations, the combined use of cetuximab and IL-2 did not improve survival of the mice compared to cetuximab alone. There are 2 possible explanations for this result. First, the number of mice we used in each group (N=5) was not enough to detect the difference. Second, the effects on tumor growth might not directly affect the survival of the mice due to distant metastasis or the side effects of IL-2, such as cardiac failure (62). Therefore, further study is warranted to determine the cause of death in these mice and to explore more effective and less toxic combination-use of IL-2.

In conclusion, cetuximab induces ADCC activity against EGFR-expressing MPM cell lines. Near-maximum ADCC activity was observed in cells with very weak EGFR expression levels, which was detectable as faint IHC staining. ADCC activity is enhanced at any EGFR expression level in the presence of low doses of IL-2. Intrathoracic administration of cetuximab in SCID mice bearing MSTO-211H cells significantly inhibited tumor growth and prolonged survival of the mice. These observations suggest the possible use of cetuximab as a novel and effective therapeutic agent that could be used in combination therapies for patients with MPM.


This study was supported by Grant-in-Aid for Scientific Research (C) 21590994 (to H.C. and E.S.) and 22590863 (to E.S. and H.C.) from the Ministry of Education, Science and Culture, Sports, Science and Technology, Japan.



L GreillierP AstoulMesothelioma and asbestos-related pleural diseasesRespiration76115200810.1159/00012757718583923


JC WagnerCA SleggsP MarchandDiffuse pleural mesothelioma and asbestos exposure in the North Western Cape ProvinceBr J Ind Med17260271196013782506


P DumortierL CopluV de MaertelaerS EmriI BarisP De VuystAssessment of environmental asbestos exposure in Turkey by bronchoalveolar lavageAm J Respir Crit Care Med15818151824199810.1164/ajrccm.158.6.97121199847273


B BarisAU DemirV ShehuY KarakocaG KisacikYI BarisEnvironmental fibrous zeolite (erionite) exposure and malignant tumors other than mesotheliomaJ Environ Pathol Toxicol Oncol1518318919969216804


P RuffieR FeldS MinkinDiffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patientsJ Clin Oncol71157116819892666592


HI PassK KrandaBK TemeckI FeuersteinSM SteinbergSurgically debulked malignant pleural mesothelioma: results and prognostic factorsAnn Surg Oncol4215222199710.1007/BF023066139142382


VW RuschS PiantadosiEC HolmesThe role of extra-pleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trialJ Thorac Cardiovasc Surg1021919912072706


NJ VogelzangJJ RusthovenJ SymanowskiPhase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaJ Clin Oncol2126362644200310.1200/JCO.2003.11.13612860938


PA JanneML TaffaroR SalgiaBE JohnsonInhibition of epidermal growth factor receptor signaling in malignant pleural mesotheliomaCancer Res6252425247200212234991


CL ArteagaEpidermal growth factor receptor dependence in human tumors: more than just expression?Oncologist7Suppl 43139200210.1634/theoncologist.7-suppl_4-3112202786


J BrabenderKD DanenbergR MetzgerEpidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survivalClin Cancer Res718501855200111448895


A DestroGL CeresoliM FalleniEGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlationsLung Cancer51207215200610.1016/j.lungcan.2005.10.01616384623


K OkudaH SasakiO KawanoEpidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesotheliomaJ Cancer Res Clin Oncol13411051111200810.1007/s00432-008-0384-418392851


LL GarlandC RankinDR GandaraPhase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group StudyJ Clin Oncol2524062413200710.1200/JCO.2006.09.763417557954


V AgarwalMJ LindL CawkwellTargeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?Cancer Treat Rev37533542201010.1016/j.ctrv.2010.11.004


ES KimV HirshT MokGefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialLancet37218091818200810.1016/S0140-6736(08)61758-419027483


FA ShepherdJ Rodrigues PereiraT CiuleanuErlotinib in previously treated non-small-cell lung cancerN Engl J Med353123132200510.1056/NEJMoa05075316014882


J AlbanellJ Codony-ServatF RojoActivated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatmentsCancer Res61650065102001


NI GoldsteinM PrewettK ZuklysP RockwellJ MendelsohnBiological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft modelClin Cancer Res11311131819959815926


DJ JonkerCJ O’CallaghanCS KarapetisCetuximab for the treatment of colorectal cancerN Engl J Med35720402048200710.1056/NEJMoa07183418003960


R GovindanRA KratzkeJE Herndon IIGefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group BClin Cancer Res1123002304200510.1158/1078-0432.CCR-04-194015788680


S LiKR SchmitzPD JeffreyJJ WiltziusP KussieKM FergusonStructural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell7301311200510.1016/j.ccr.2005.03.00315837620


JD SatoT KawamotoAD LeJ MendelsohnJ PolikoffGH SatoBiological effects in vitro of monoclonal antibodies to human epidermal growth factor receptorsMol Biol Med151152919836094961


GN GillT KawamotoC CochetMonoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activityJ Biol Chem259775577601984


T KawamotoJD SatoA LeJ PolikoffGH SatoJ MendelsohnGrowth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibodyProc Natl Acad Sci USA8013371341198310.1073/pnas.80.5.1337


M NaramuraSD GilliesJ MendelsohnRA ReisfeldBM MuellerTherapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanomaCancer Immunol Immunother37343349199310.1007/BF015184588402738


J KuraiH ChikumiK HashimotoAntibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell linesClin Cancer Res1315521561200710.1158/1078-0432.CCR-06-172617332301


H KimuraK SakaiT AraoT ShimoyamaT TamuraK NishioAntibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptorCancer Sci9812751280200710.1111/j.1349-7006.2007.00510.x17498200


CS HenneyK KuribayashiDE KernS GillisInterleukin-2 augments natural killer cell activityNature291335338198110.1038/291335a06164929


Z LiuFT LeeN HanaiCytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871Cancer Immun213200212747758


QH NguyenRL RobertsBJ AnkSJ LinCK LauER StiehmEnhancement of antibody-dependent cellular cytotoxicity of neonatal cells by interleukin-2 (IL-2) and IL-12Clin Diagn Lab Immunol59810419989455889


E NakatakiS YanoY MatsumoriNovel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptorCancer Sci97183191200610.1111/j.1349-7006.2006.00163.x


GJ TodaroJE De LarcoGrowth factors produced by sarcoma virus-transformed cellsCancer Res38414741541978212188


CJ WikstrandRE McLendonAH FriedmanDD BignerCell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIIICancer Res574130414019979307304


G BrockhoffF HofstaedterR KnuechelFlow cytometric detection and quantitation of the epidermal growth factor receptor in comparison to Scatchard analysis in human bladder carcinoma cell linesCytometry177583199410.1002/cyto.9901701108001460


K DorshkindSB PollackMJ BosmaRA PhillipsNatural killer (NK) cells are present in mice with severe combined immunodeficiency (scid)J Immunol1343798380119853989296


FR LuoZ YangH DongCorrelation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograftCancer Chemother Pharmacol56455464200510.1007/s00280-005-1022-315947929


R NiwaM SakuradaY KobayashiEnhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen densityClin Cancer Res1123272336200510.1158/1078-0432.CCR-04-2263


N PrangS PreithnerK BrischweinCellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell linesBr J Cancer92342349200515655555


A RalletMJ FarouxS TheobaldEpidermal growth factor receptors in breast cancer: comparison of radioligand and immunocytochemical assaysAnticancer Res141417142119948067716


JG KlijnPM BernsPI SchmitzJA FoekensThe clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patientsEndocr Rev1331719921313356


R KimmigD PfeifferH LandsmannH HeppQuantitative determination of the epidermal growth factor receptor in cervical cancer and normal cervical epithelium by 2-color flow cytometry: evidence for down-regulation in cervical cancerInt J Cancer74365373199710.1002/(SICI)1097-0215(19970822)74:4%3C365::AID-IJC1%3E3.0.CO;2-T


KA SmithInterleukin-2: inception, impact, and implicationsScience24011691176198810.1126/science.31318763131876


E HooijbergJJ SeinPC van den BerkEradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2Cancer Res552627263419957540106


J GolayM ManganiniV FacchinettiRituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2Haematologica8810021012200312969808


M KuboT MorisakiH KurokiCombination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancerAnticancer Res2344434449200314666732


WE CarsonR PariharMJ LindemannInterleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cellsEur J Immunol3130163025200110.1002/1521-4141(2001010)31:10%3C3016::AID-IMMU3016%3E3.0.CO;2-J11592078


K KonoA TakahashiF IchiharaH SugaiH FujiiY MatsumotoImpaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancerCancer Res6258135817200212384543


AD SantinS BelloneM GokdenOverexpression of HER-2/neu in uterine serous papillary cancerClin Cancer Res812711279200212006548


N BerinsteinR LevyTreatment of a murine B cell lymphoma with monoclonal antibodies and IL-2J Immunol13997197619873496394


WM VuistF v BuitenenMA de RieA HekmanP RumkeCJ MeliefPotentiation by interleukin 2 of Burkitt’s lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation modelCancer Res49378337881989


WL GluckD HurstA YuenPhase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin’s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical responseClin Cancer Res10225322642004


GF FlemingNJ MeropolGL RosnerA phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661Clin Cancer Res837183727200212473581


T RepkaEG ChioreanJ GayTrastuzumab and inter-leukin-2 in HER2-positive metastatic breast cancer: a pilot studyClin Cancer Res924402446200312855616


M SuzukiM Kato-NakanoS KawamotoTherapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancersCancer Sci10016231630200910.1111/j.1349-7006.2009.01239.x19555390


DE Lopes de MenezesK Denis-MizeY TangRecombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphomaJ Immunother306474200717198084


JM RodaT JoshiJP ButcharThe activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokinesClin Cancer Res1364196428200710.1158/1078-0432.CCR-07-086517962339


T AzizA JilaihawiD PrakashThe management of malignant pleural mesothelioma; single centre experience in 10 yearsEur J Cardiothorac Surg22298305200212142203


O MonneuseAC BeaujardB GuibertLong-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignanciesBr J Cancer8818391843200310.1038/sj.bjc.660100012799624


H SchouwinkET RutgersJ van der SijpIntraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity resultsChest12011671174200110.1378/chest.120.4.1167


W Den OtterJJ JacobsJJ BattermannLocal therapy of cancer with free IL-2Cancer Immunol Immunother57931950200818256831


B CastagnetoS ZaiL MuttiPalliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patientsLung Cancer31303310200110.1016/S0169-5002(00)00192-6

Related Articles

Journal Cover

November 2012
Volume 41 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
Kurai, J., Chikumi, H., Hashimoto, K., Takata, M., Sako, T., Yamaguchi, K. ... Shimizu, E. (2012). Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma. International Journal of Oncology, 41, 1610-1618.
Kurai, J., Chikumi, H., Hashimoto, K., Takata, M., Sako, T., Yamaguchi, K., Kinoshita, N., Watanabe, M., Touge, H., Makino, H., Igishi, T., Hamada, H., Yano, S., Shimizu, E."Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma". International Journal of Oncology 41.5 (2012): 1610-1618.
Kurai, J., Chikumi, H., Hashimoto, K., Takata, M., Sako, T., Yamaguchi, K., Kinoshita, N., Watanabe, M., Touge, H., Makino, H., Igishi, T., Hamada, H., Yano, S., Shimizu, E."Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma". International Journal of Oncology 41, no. 5 (2012): 1610-1618.